Non-flavonoid polyphenols in osteoporosis: preclinical evidence

Trends Endocrinol Metab. 2021 Jul;32(7):515-529. doi: 10.1016/j.tem.2021.03.008. Epub 2021 Apr 21.

Abstract

The development of progressive osteopenia and osteoporosis (OP) is due to the imbalance between bone resorption and bone formation, determining a lower bone resistance, major risks of fractures, with consequent pain and functional limitations. Flavonoids, a class of polyphenols, have been extensively studied for their therapeutic activities against bone resorption, but less attention has been given to a whole series of molecules belonging to the polyphenolic compounds. However, these classes have begun to be studied for the treatment of OP. In this systematic review, comprehensive information is provided on non-flavonoid polyphenolic compounds, and we highlight pathways implicated in the action of these molecules that act often epigenetically, and their possible use for OP treatment and prevention.

Keywords: bone erosive diseases; epigenetics; osteoblast; osteoclast; osteoporosis; polyphenolic compounds.

Publication types

  • Research Support, Non-U.S. Gov't
  • Systematic Review

MeSH terms

  • Bone Resorption*
  • Flavonoids / therapeutic use
  • Humans
  • Osteogenesis
  • Osteoporosis* / drug therapy
  • Polyphenols / pharmacology
  • Polyphenols / therapeutic use

Substances

  • Flavonoids
  • Polyphenols